Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Alejandro Bertolet, Ph.D.

Title
Institution
Department
Address
Profile Picture

Biography
Universidad de Sevilla, Seville, SpainBS09/2014Physics
Hospital Universitario Virgen Macarena, Seville, SpainMedPhys05/2018Clinical Medical Physics
Universidad Nacional de Educación a Distancia, Madrid, SpainMSc06/2018Medical Physics
Universidad de Sevilla, Seville, SpainPhD09/2020Radiation Biophysics

Overview

Mentoring
Available: 12/01/23, Expires: 09/01/24

Transarterial radioembolization (TARE) is one of the therapeutic options to treat unresectable hepatocellular carcinoma (HCC) and other liver-related cancers. This procedure employs microspheres equipped with a radioactive isotope delivered through the hepatic artery so that they get lodged in the small vessels near the tumor. This is favored by the preferential blood flow towards the tumor with respect to the healthy liver. Radiation emitted near the tumor is utilized for therapeutic effect. Despite the success of TARE as an effective treatment for HCC, patient-specific optimization is expected to lead to large improvements in treatment response. In this project, the student will join a multi-disciplinary team, including physicians, physicists, and machine-learning engineers, to study the patient-specific factors and biomarkers impacting the response to TARE treatments, as well as the relationship between radiation dose and clinical outcomes.


Research
The research activities and funding listed below are automatically derived from NIH ExPORTER and other sources, which might result in incorrect or missing items. Faculty can login to make corrections and additions.
  1. 1R21CA279068-01 (BERTOLET REINA, ALEJANDRO) Sep 8, 2023 - Sep 7, 2025
    NIH/NCI
    GPU-based SPECT reconstruction using reverse Monte Carlo simulations
    Role Description: This project explores a GPU-accelerated Monte Carlo method with reverse physics for SPECT reconstruction
    Role: PI
  2. 1R01CA278882-01 (PRYMA, DANIEL) Sep 1, 2023 - Aug 31, 2028
    NIH/NCI
    Optimizing theranostic radiopharmaceutical therapy to combat resistance to PARP inhibition in advanced ovarian cancer
    Role Description: In this project, we aim to better understand the comparative radiobiology of the alpha emitting drug [211At]PTT in tumor and normal tissues. We will develop an optimized strategy for translation to clinical trials in women with advanced PARPi resistant ovarian cancer. The PET imaging companion diagnostic [18F]FTT will be developed in parallel as a prognostic biomarker as well as for image-guided treatment planning.
    Role: Site PI
  3. 2022 Warshaw Institute Research Pilot Grant Fundin (BERTOLET REINA, ALEJANDRO) Jul 1, 2022 - Dec 31, 2023
    Andrew L. Warshaw, M.D., Institute for Pancreatic Cancer Research, Massachusetts General Hospital
    Radiobiological modeling of alpha-particle radiopharmaceutical therapy for pancreatic adenocarcinoma
    Role Description: Providing valuable knowledge to guide the design of new pre-clinical studies in which our results can be validated; and modeling different factors impacting the dosimetry and biological effects of a-particles with the future ambition of optimizing clinical treatments of pancreatic ductal adenocarcinoma.
    Role: PRINCIPAL INVESTIGATOR
  4. K99CA267560 (BERTOLET REINA, ALEJANDRO) Dec 10, 2021 - Nov 30, 2023
    NIH/NCI
    Radiation dosimetry for alpha-particle radiopharmaceutical therapy and application to pediatric neuroblastoma
    Role Description: The project will study radiopharmaceutical treatments with a-particles, focusing on the treatment of pediatric neuroblastoma using the radiopharmaceutical [211At]MM4, which targets the overexpression of PARP-1 proteins in pediatric neuroblastoma tumors.
    Role: PRINCIPAL INVESTIGATOR

Featured Content

Bibliographic
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
Updating...
This operation might take several minutes to complete. Please do not close your browser.
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact contactcatalyst.harvard.edu. For faculty or fellow appointment updates and changes, please ask your appointing department to contact HMS. For fellow personal and demographic information, contact HMS Human Resources at human_resourceshms.harvard.edu. For faculty personal and demographic information, contact HMS Office for Faculty Affairs at facappthms.harvard.edu.
Bertolet's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts (62)
Explore
_
Co-Authors (17)
Explore
_
Similar People (60)
Explore
_
Same Department 
Explore
_
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.